Company MyMD Pharmaceuticals, Inc.

Equities

MYMD

US62856X2018

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-22 pm EDT			5-day change	1st Jan Change
2.58 ^USD	+3.20%		+13.66%	-66.76%

Apr. 18	MyMD Pharmaceuticals, Inc. Announces Resignation of Adam Kaplin as Chief Scientific Officer	CI
Apr. 09	Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data	MT

MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. The Companyâs MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. It also shows potential as an anti-fibrotic and anti-prolific therapeutic. The Companyâs second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. Supera-CBD is a synthetic, preclinical cannabidiol derivative that has been demonstrated to effectively target cannabinoid type 2 (CB2) receptors. Supera-CBD binds to and inhibits opioid receptors, comparing it side by side with plant-based cannabidiol (CBD).

Number of employees: 6

Managers	Title	Age	Since
Christopher Chapman PSD	President	71	20-10-31
Ian Rhodes DFI	Director of Finance/CFO	51	21-04-14
Christopher Schreiber BRD	Director/Board Member	58	17-08-07
Robert Schatz IRC	Investor Relations Contact	-	-
Jenna Brager LAW	General Counsel	-	21-04-30

Members of the board	Title	Age	Since
Christopher Schreiber BRD	Director/Board Member	58	17-08-07
Christopher Chapman PSD	President	71	20-10-31
Joshua Silverman CHM	Chairman	53	18-09-05
Bill White BRD	Director/Board Member	63	17-08-07
Craig Eagle BRD	Director/Board Member	57	21-04-15
Jude Uzonwanne BRD	Director/Board Member	50	21-04-15

	Vote	Quantity	Free-Float	Total Float
Stock A	0	9,859	0	92.68 %
Stock B	0	72,992	0
Stock C	1	2,157,632	1,999,627 ( 92.68 %)

Name	Equities	%	Valuation
Caroline C Williams 5.785 %	124,815	5.785 %	298 308 $
Global X Management Co. LLC 4.802 %	103,615	4.802 %	247 640 $
Samuel Duffey 3.165 %	68,295	3.165 %	163 225 $
Vanguard Global Advisers LLC 2.253 %	48,609	2.253 %	116 176 $
Richard Abbe 1.427 %	30,791	1.427 %	73 590 $
Paul Rivard 0.6180 %	13,334	0.6180 %	31 868 $
Geode Capital Management LLC 0.4499 %	9,708	0.4499 %	23 202 $
BlackRock Institutional Trust Co. NA 0.3069 %	6,622	0.3069 %	15 827 $
Iroquois Capital Management LLC 0.2895 %	6,247	0.2895 %	14 930 $
Cambria Investment Management LP 0.2651 %	5,719	0.2651 %	13 668 $

Name	Equities	%	Valuation
Iroquois Capital Management LLC 13.89 %	2,083	13.89 %	4 978 $

Name	Equities	%	Valuation
Premas Biotech Pvt Ltd. 34.54 %	72,992	34.54 %	174 451 $

MyMD Pharmaceuticals, Inc.

855 North Wolfe Street Suite 601

21205, Baltimore

http://www.mymd.com

address MyMD Pharmaceuticals, Inc.(MYMD)

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
MYMD PHARMACEUTICALS, INC.	-66.76%	5.57M
REGENERON PHARMACEUTICALS, INC.	+2.49%	96.73B
ARGENX SE	-0.23%	21.31B
BIONTECH SE	-16.61%	21.21B
GENMAB A/S	-5.10%	18.79B
WUXI APPTEC CO., LTD.	-42.14%	16.37B
BEIGENE, LTD.	-27.40%	13.68B
NEUROCRINE BIOSCIENCES, INC.	+1.44%	13.44B
SAREPTA THERAPEUTICS, INC.	+21.29%	10.98B
LEGEND BIOTECH CORPORATION	-21.79%	8.56B

Bio Therapeutic Drugs